Xencor_XmAb819-01 (Clear Cell Renal Cell Carcinoma) - Clinical Trial

What is the Purpose of this Study?

We are doing this study to find out if an experimental drug called XmAb819 (the study drug) is a safe and effective treatment for clear cell renal cell carcinoma (ccRCC).

What is the Condition Being Studied?

Clear Cell Renal Cell Carcinoma (ccRCC)

Who Can Participate in the Study?

Adults ages 18+ who:

- Are diagnosed with ccRCC

- Have not improved after receiving standard therapy

For more information about who can join this study, please contact the study team at 919-681-6468.

Age Group
Adults

What is Involved?

If you choose to join this study, you will:

- Get the study drug as either an intravenous infusion (IV) or as an injection under your skin

- Have a tumor biopsy

- Have physical exams, blood draws, and give urine samples

- Have imaging scans (CT and/or MRI)

- Have heart tests (ECG)

Study Details

Full Title
A Phase 1, Multiple-Dose Study to Evaluate the Safety and Tolerability of XmAb819 in Subjects with Relapsed or Refractory Clear Cell Renal Cell Carcinoma
Principal Investigator
Christopher Hoimes
Protocol Number
IRB: PRO00111480
NCT: NCT05433142
Phase
Phase I
ClinicalTrials.gov
Enrollment Status
Open for Enrollment